TCB Team is a group of domain experts and writers focused on biotech, healthcare, and AI. They deliver original, high-signal coverage tailored for industry professionals, investors, and researchers. With a neutral and independent voice, the team transforms complex developments into clear, actionable insights.
110 articlesMostly Regulatory & Policy and Biopharmaceutical Industry
Regulatory & PolicyThis policy shift by the FDA signals a new era of deregulation to promote AI use in healthcare technologies, balancing innovation with appropriate safeguards.
TCB TeamJan 8, 2026
Biotech InnovationAfter two successful Phase 3 studies, GSK's bepirovirsen demonstrates functional cure rates for chronic hepatitis B patients, potentially providing an alternative to lifelong antiviral regimens.
TCB TeamJan 8, 2026
Biopharmaceutical IndustryNew clinical data suggest bepirovirsen could offer a finite treatment alternative to lifelong antivirals for chronic hepatitis B infection. Achieving functional cure after six months marks a potential paradigm shift in this infectious disease area.
TCB TeamJan 8, 2026
Regulatory & PolicyNew policy shifts by the U.S. FDA seek to deregulate AI-enabled medical devices and wearables to promote innovation and integration within healthcare, marking a significant regulatory pivot in digital health oversight.
TCB TeamJan 8, 2026
Healthcare InvestmentJ.P. Morgan’s report highlights unprecedented dealmaking in obesity and diabetes sectors in 2025. The surge in mergers and acquisitions contrasts with downward trends in other investment forms, signaling strategic consolidation in this therapeutic area.
TCB TeamJan 8, 2026
Biopharmaceutical IndustryDark Blue Therapeutics' lead asset is a small-molecule degrader of MLLT1 and MLLT3 proteins currently being tested in acute myeloid leukemia (AML). This acquisition is part of Amgen's strategic push into innovative cancer therapies in the hematology space.
TCB TeamJan 7, 2026
Regulatory & PolicyThe latest dietary guidelines recommend increased protein and dairy consumption while reducing sugar and processed food intake. However, scrutiny arises due to the advisory panel's financial ties to industries that benefit from these changes. This controversy comes amid criticism from figures like Robert F. Kennedy Jr. regarding corporate influence in public health policies.
TCB TeamJan 7, 2026
Biotech InnovationGSK’s bepirovirsen achieved its primary endpoint in late-stage clinical trials, potentially offering an alternative to lifelong antiviral treatments for patients with chronic hepatitis B infection. This development marks a significant step toward a functional cure for the disease.
TCB TeamJan 7, 2026
Biotech InnovationWith rapid advancements and investments, China is closing the gap on biotech research and development. This change could reshape competitive dynamics and investment flows in the industry.
TCB TeamJan 7, 2026
Biopharmaceutical IndustryVentyx Biosciences is developing oral treatments targeting autoimmune conditions, complementing Lilly's expanding focus on this therapeutic area. The potential deal highlights ongoing consolidation in biotech.
TCB TeamJan 7, 2026
Biopharmaceutical IndustryThe acquisition, valued at up to $840 million, strengthens Amgen's oncology pipeline with a drug candidate addressing challenging leukemia markers, signaling commitment to hematologic cancers.
TCB TeamJan 7, 2026
Regulatory & PolicyIn a significant policy shift aimed at accelerating innovation and access, the FDA will reduce its regulatory burden on AI-powered and wearable health technology. This move reflects a strategic decision to facilitate the expansion of AI use in healthcare while balancing safety and efficacy.
TCB TeamJan 6, 2026